BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
A phase 1/2 trial of BXQ-350 in colorectal cancer, run by Bexion Pharmaceuticals, Inc., active and no longer recruiting.
Overview
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma is a phase 1/2 interventional study registered as NCT05322590 by Bexion Pharmaceuticals, Inc., with 195 participants enrolled, started 2023-01-09 and due to reach its primary completion in 2026-04. Interventions recorded: BXQ-350.
Similar pages
not linked directly; found by shared links- TrialA Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Shares ICON plc and the tag pipeline.
- TrialA Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Shares ICON plc and the tag pipeline.
- TrialXian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA First-In-Human Trial of pTTL in Advanced Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialEvaluation of Gixam's Performance in a FIT Negative Population
Shares Colorectal cancer and the tag pipeline.
- TrialIsunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
Shares Colorectal cancer and the tag pipeline.
- TrialTo Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.
Shares Colorectal cancer and the tag pipeline.